MedTrace Logo

Photosensitization Study in Androgenetic Alopecia

NCT02791243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-05-18

No results posted yet for this study

Summary

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)

Conditions

Interventions

DRUG

Finasteride 0.25%

Cutaneous solution of finasteride 0.25%

DRUG

Placebo for Finasteride 0.25%

vehicle cutaneous solution of P-3074

DRUG

Negative Control

0.9% aqueous NaCl

Sponsors & Collaborators

  • Polichem S.A.

    lead INDUSTRY

Principal Investigators

  • Michael Carr, MD · Princeton Consumer Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-09
Primary Completion
2016-06-30
Completion
2016-06-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02791243 on ClinicalTrials.gov